HC Wainwright Reiterates Buy Rating for Incyte (NASDAQ:INCY)

Incyte (NASDAQ:INCY)‘s stock had its “buy” rating reissued by analysts at HC Wainwright in a note issued to investors on Wednesday,Benzinga reports. They presently have a $135.00 price target on the biopharmaceutical company’s stock. HC Wainwright’s price target would indicate a potential upside of 34.93% from the company’s current price.

A number of other analysts also recently commented on the company. Wells Fargo & Company reissued an “equal weight” rating and issued a $107.00 price objective (down previously from $116.00) on shares of Incyte in a research note on Tuesday, January 20th. Zacks Research lowered Incyte from a “strong-buy” rating to a “hold” rating in a report on Monday, November 10th. Piper Sandler boosted their price target on shares of Incyte from $102.00 to $110.00 and gave the stock an “overweight” rating in a research report on Friday. Barclays upped their price target on shares of Incyte from $115.00 to $116.00 and gave the company an “overweight” rating in a report on Wednesday, February 4th. Finally, Wall Street Zen raised shares of Incyte from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 1st. Nine investment analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $103.29.

Incyte Trading Down 8.2%

Incyte stock opened at $100.05 on Wednesday. Incyte has a 52-week low of $53.56 and a 52-week high of $112.29. The company has a quick ratio of 3.13, a current ratio of 3.20 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $19.64 billion, a price-to-earnings ratio of 16.76, a PEG ratio of 0.65 and a beta of 0.82. The firm has a 50-day moving average price of $101.80 and a two-hundred day moving average price of $93.78.

Incyte (NASDAQ:INCY) last issued its quarterly earnings data on Tuesday, February 10th. The biopharmaceutical company reported $1.80 earnings per share for the quarter, missing analysts’ consensus estimates of $1.96 by ($0.16). The company had revenue of $1.51 billion for the quarter, compared to the consensus estimate of $1.35 billion. Incyte had a net margin of 24.69% and a return on equity of 26.56%. Incyte’s revenue for the quarter was up 27.8% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.43 earnings per share. Sell-side analysts expect that Incyte will post 4.86 earnings per share for the current year.

Insider Activity

In other Incyte news, insider Thomas Tray sold 2,774 shares of the stock in a transaction that occurred on Friday, December 19th. The shares were sold at an average price of $100.00, for a total value of $277,400.00. Following the completion of the sale, the insider owned 22,973 shares in the company, valued at $2,297,300. This represents a 10.77% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Michael James Morrissey sold 4,323 shares of the company’s stock in a transaction dated Wednesday, December 17th. The stock was sold at an average price of $97.26, for a total value of $420,454.98. Following the completion of the transaction, the executive vice president directly owned 27,507 shares in the company, valued at approximately $2,675,330.82. The trade was a 13.58% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 95,225 shares of company stock valued at $9,519,745 in the last 90 days. Company insiders own 17.80% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Arrowstreet Capital Limited Partnership grew its holdings in Incyte by 701.8% during the second quarter. Arrowstreet Capital Limited Partnership now owns 2,730,648 shares of the biopharmaceutical company’s stock valued at $185,957,000 after purchasing an additional 2,390,084 shares during the period. AQR Capital Management LLC boosted its position in shares of Incyte by 21.8% during the second quarter. AQR Capital Management LLC now owns 8,201,455 shares of the biopharmaceutical company’s stock worth $558,519,000 after purchasing an additional 1,465,286 shares in the last quarter. Norges Bank acquired a new position in shares of Incyte in the 2nd quarter valued at $96,776,000. Pacer Advisors Inc. increased its position in shares of Incyte by 8,091.6% in the 3rd quarter. Pacer Advisors Inc. now owns 1,248,642 shares of the biopharmaceutical company’s stock valued at $105,897,000 after buying an additional 1,233,399 shares in the last quarter. Finally, Marshall Wace LLP acquired a new stake in Incyte during the 2nd quarter worth $82,485,000. Institutional investors and hedge funds own 96.97% of the company’s stock.

Key Stories Impacting Incyte

Here are the key news stories impacting Incyte this week:

• Positive Sentiment: H.C. Wainwright reiterated a Buy rating with a $135 price target, citing long-term revenue durability and an underappreciated pipeline, which supports upside potential if pipeline assets progress. Incyte: Long-Term Revenue Durability and Underappreciated Pipeline Support Buy Rating and $135 Target
• Neutral Sentiment: Top-line strength: Q4 revenue of ~$1.51B beat consensus (~$1.35B) and rose ~28% YoY, driven by Jakafi and Opzelura product sales — a positive operating signal even as EPS missed. Earnings Release / Slides
• Neutral Sentiment: Company commentary and the earnings call highlighted pipeline progress and strategic focus beyond Jakafi, which could mitigate long-term risk if clinical readouts are favorable. Earnings Call Highlights
• Negative Sentiment: EPS miss: Q4 EPS $1.80 vs. consensus ~$1.96, which, together with a softer 2026 revenue forecast, pressured sentiment and valuations. Zacks: INCY Q4 Earnings Miss
• Negative Sentiment: Guidance and Jakafi risk: Management’s weak 2026 revenue outlook and commentary that Opzelura may underperform heightens concerns about replacing revenue when Jakafi faces patent expiry/generic competition. This is the main driver of today’s selloff. Reuters: Weak 2026 Forecast
• Neutral Sentiment: Market/coverage notes and transcripts are available (Seeking Alpha, Yahoo) for investors wanting the full call and management commentary to model 2026 scenarios. Earnings Call Transcript Press Release
• Neutral Sentiment: Short-interest data reported appears anomalous (zeros) and is unlikely to explain intra-day moves; focus remains on guidance and product dynamics.

About Incyte

Incyte Corporation is a Wilmington, Delaware–based biopharmaceutical company focused on the discovery, development and commercialization of novel therapies in oncology and inflammation. Since its founding in 2002, Incyte has grown from a small research organization into a global enterprise, advancing a portfolio of internally developed and partnered assets. The company’s research and development efforts center on small-molecule drugs and biologics that modulate critical signaling pathways implicated in cancer, autoimmune disorders and rare diseases.

The company’s flagship product is Jakafi® (ruxolitinib), a Janus kinase (JAK) inhibitor approved for the treatment of myelofibrosis and polycythemia vera.